RGC

US stock futures are slightly lower this morning, with S&P 500 contracts off about 0.2%, as investors weigh fresh inflation clues against mixed global growth signals. The key focus is the US Producer Price Index, expected to rise 0.2% in November and sit at 2.7% over the past year, which is a scorecard for what businesses pay for goods and services and a hint of future price pressures for consumers. At the same time, the World Bank now sees global growth at 2.6% in 2026, and China has reported a US$1.189b trade surplus. These developments put cost of living trends and global demand in the spotlight for rate-sensitive sectors such as real estate and utilities, as well as internationally exposed manufacturers and commodity producers, and leave investors considering how much inflation risk they want to take on in exchange traded funds or broad index exposure. Worried about inflation squeezing returns? Filter for undervalued stocks based on cash flows before today’s moves leave fewer clear options. Roblox (RBLX) jumped 10.53% after Morgan Stanley highlighted continued hit titles supporting bookings momentum. Intel (INTC) gained 7.33% after a KeyBanc upgrade citing strong server CPU and data center demand. Strategy (MSTR) climbed 6.63% on buying interest following recent volatility in the stock. Is Strategy still a smart investment or just hype? Read our most popular narrative and get all the answers you need. Regencell Bioscience Holdings (RGC) declined 26.23%. Salesforce (CRM) declined 7.07% following recent product and client related announcements. Atlassian (TEAM) declined 5.84% after the company set its next earnings release date. Look past the noise - uncover the top narrative that explains what truly matters for Regencell Bioscience Holdings' long-term success. Big U.S. banks and fresh inflation data are set to frame the next few sessions for equity investors. Bank earnings cluster: Bank of America (BAC), Wells Fargo (WFC) and Citigroup (C) report Q4 on Wednesday, shaping the read on large lenders. Producer prices: The U.S. PPI report on Wednesday highlights input cost trends that feed directly into inflation expectations. Wall Street heavyweights: Goldman Sachs (GS), Morgan Stanley (MS) and BlackRock (BLK) post Q4 results on Thursday, spotlighting capital markets and asset management activity. Transport readthrough: J.B. Hunt Transport Services (JBHT) rep...

We recently compiled a list of the 12 Healthcare Stocks with Insider Buying in 2025. Regencell Bioscience Holdings Limited is one of them. Regencell Bioscience Holdings Limited (NASDAQ:RGC) tops our list for being one of the stocks with insider buying. It is a Hong Kong-based biopharmaceutical company developing Traditional Chinese Medicine (TCM) treatments for neurocognitive disorders such as ADHD and autism spectrum disorder (ASD). A key milestone came on September 21, 2025, when RGC was added to the S&P Global BMI Index, boosting its visibility among institutional and passive investors. This inclusion may enhance liquidity and help stabilize the stock, which has been highly volatile. Despite this progress, the business continues to face fundamental challenges, including zero revenue, ongoing losses, and uncertain regulatory pathways for its treatments. On the clinical front, Regencell Bioscience Holdings Limited (NASDAQ:RGC) reported positive results from its second efficacy trial using standardized TCM formulae for ADHD and ASD, showing a mean symptom improvement of 37% with no adverse side effects. While encouraging, no FDA-approved products have been announced yet, and the treatments remain investigational. Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock experienced extreme volatility in mid-2025, peaking with an approximate 14,899% year-to-date gain by June, driven by speculative trading, a stock split, and excitement over trial results. Following this peak, shares saw sharp intra-day swings and a pullback, though technical indicators in September suggest a potential upward trend, supported by positive momentum and movement above its 50-day moving average. While we acknowledge the potential of RGC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW Disclosure: None.